KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

NCT03925974 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric/Gastroesophageal Junction Cancer

Interventions

DRUG: KN026 10 mg/kg QW
DRUG: KN026 20 mg/kg Q2W
DRUG: KN026 30 mg/kg Q3W

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd